Skip to main content
Have a personal or library account? Click to login
Pulmonary Hypertension in Women Cover
By:  and    
Open Access
|Mar 2024

References

  1. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892.
  2. Swisher JW, Weaver E. The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Vasc Health Risk Manag. 2023 Mar 3;19:103-126. doi: 10.2147/VHRM.S321025
  3. Humbert M, Kovacs G, Hoeper MM, et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023 Jan 6;61(1):2200879. doi: 10.1183/13993003.00879-2022
  4. Franco V, Ryan JJ, McLaughlin VV. Pulmonary Hypertension in Women. Heart Fail Clin. 2019 Jan;15(1):137-145. doi: 10.1016/j.hfc.2018.08.013
  5. Cheron C, McBride SA, Antigny F, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev. 2021 Nov 8;30(162):200330. doi: 10.1183/16000617.0330-2020
  6. Morris H, Denver N, Gaw R, Labazi H, Mair K, MacLean MR. Sex Differences in Pulmonary Hypertension. Clin Chest Med. 2021 Mar;42(1):217-228. doi: 10.1016/j.ccm.2020.10.005
  7. Safdar Z. Pulmonary hypertension: a woman’s disease. Tex Heart Inst J. 2013;40(3):302-3. PMID: 23914026
  8. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023
  9. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012 Mar 1;21(123):8-18. doi: 10.1183/09059180.00008211
  10. Escribano-Subias P, Blanco I, López-Meseguer M, et al.; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012 Sep;40(3):596-603. doi: 10.1183/09031936.00101211
  11. Skride A, Sablinskis K, Lejnieks A, Rudzitis A, Lang I. Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulm Circ. 2018 Jul-Sep;8(3):2045894018780521. doi: 10.1177/2045894018780521
  12. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012 Feb;141(2):363-373. doi: 10.1378/chest.10-3114
  13. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026
  14. Tamura Y, Kumamaru H, Satoh T, et al.; Japan PH Registry (JAPHR) Network. Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J. 2017 Dec 25;82(1):275-282. doi: 10.1253/circj.CJ-17-0139
  15. Sithamparanathan S, Nair A, Thirugnanasothy L, et al.; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014
  16. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007 Jul;30(1):104-9. doi: 10.1183/09031936.00092306
  17. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 Jul 13;122(2):156-63. doi: 10.1161/CIRCULATIONAHA.109.911818
  18. Rodriguez-Arias JJ, García-Álvarez A. Sex Differences in Pulmonary Hypertension. Front Aging. 2021 Oct 4;2:727558. doi: 10.3389/fragi.2021.727558
  19. Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014 Jul 1;307(1):L7-26. doi: 10.1152/ajplung.00337.2013
  20. Gomez-Arroyo J, Saleem SJ, Mizuno S, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011
  21. Sun Y, Sangam S, Guo Q, et al. Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. Front Cardiovasc Med. 2021 Sep 10;8:719058. doi: 10.3389/fcvm.2021.719058
  22. Hester J, Ventetuolo C, Lahm T. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. Compr Physiol. 2019 Dec 18;10(1):125-170. doi: 10.1002/cphy.c190011
  23. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014 Feb;171(3):567-79. doi: 10.1111/bph.12281
  24. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1):1801889. doi: 10.1183/13993003.01889-2018
  25. Humbert M, McLaughlin V, Gibbs JSR, et al.; PULSAR Trial Investigators. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277
  26. Hoeper MM, Badesch DB, Ghofrani HA, et al.; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558
  27. Frantz RP, Benza RL, Channick RN, et al. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulm Circ. 2021 Nov 11;11(4):20458940211057071. doi: 10.1177/20458940211057071
  28. Gillies H, Niven R, Dake BT, et al. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. ERJ Open Res. 2023 Mar 13;9(2):00433-2022. doi: 10.1183/23120541.00433-2022
  29. Oliveira LFTS, Chiavegato LD, Arakaki JSO, et al. Prevalence of sexual dysfunction in women with pulmonary hypertension and associated factors. Heart Lung. 2021 Sep-Oct;50(5):714-719. doi: 10.1016/j.hrtlng.2021.04.018
  30. Guillevin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev. 2013 Dec;22(130):535-42. doi: 10.1183/09059180.00005713
  31. Cipolletta S, Ravasio G, Bussotti M. Sexual and Reproductive Health in Women with Pulmonary Hypertension: A Qualitative Study. Arch Sex Behav. 2022 Apr;51(3):1647-1657. doi: 10.1007/s10508-022-02284-w
  32. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec;25(142):431-437. doi: 10.1183/16000617.0079-2016
  33. Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin Respir Crit Care Med. 2013 Oct;34(5):681-8. doi: 10.1055/s-0033-1355438
  34. Ma R, Gao H, Cui J, et al. Pregnancy feasibility in women with mild pulmonary arterial hypertension: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023 Jun 8;23(1):427. doi: 10.1186/s12884-023-05752-w
  35. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. doi: 10.1055/s-2003-38897
  36. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015 Sep;5(3):435-65. doi: 10.1086/682230
  37. Chen W, Luo J, Chen J, et al. Effect of multidisciplinary team (MDT) centred on pregnant women with pulmonary hypertension on treatment and outcomes of pregnancy. BMC Pulm Med. 2023 Feb 11;23(1):62. doi: 10.1186/s12890-023-02355-1
  38. Vaidya A, Oliveros E, Mulla W, Feinstein D, Hart L, Forfia P. Management of Pulmonary Arterial Hypertension in Pregnancy: Experience from a Nationally Accredited Center. J Cardiovasc Dev Dis. 2022 Jun 18;9(6):195. doi: 10.3390/jcdd9060195
  39. Safdar Z. Pulmonary arterial hypertension in pregnant women. Ther Adv Respir Dis. 2013 Feb;7(1):51-63. doi: 10.1177/1753465812461680
  40. Griva P, Stamatakis E, Varvarousi G, Loukeri A, Valsamidis D. The Use of Vigileo® Monitor in a Parturient With Severe Mitral Valve Stenosis and Severe Pulmonary Hypertension Undergoing Cesarean Section Under General Anesthesia: A Case Report and Literature Review. Cureus. 2022 Dec 7;14(12):e32284. doi: 10.7759/cureus.32284
  41. Zhang Q, Zhu F, Shi G, et al. Maternal Outcomes Among Pregnant Women With Congenital Heart Disease-Associated Pulmonary Hypertension. Circulation. 2023 Feb 14;147(7):549-561. doi: 10.1161/CIRCULATIONAHA.122.057987
  42. Ma L, Liu W, Huang Y. Perioperative management for parturients with pulmonary hypertension: experience with 30 consecutive cases. Front Med. 2012 Sep;6(3):307-10. doi: 10.1007/s11684-012-0209-3
  43. Lv C, Huang Y, Liao G, Wu L, Chen D, Gao Y. Pregnancy outcomes in women with pulmonary hypertension: a retrospective study in China. BMC Pregnancy Childbirth. 2023 Jan 9;23(1):16. doi: 10.1186/s12884-023-05353-7
  44. Corbach N, Berlier C, Lichtblau M, et al. Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. Front Med (Lausanne). 2021 Jul 5;8:689764. doi: 10.3389/fmed.2021.689764
  45. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013 May;143(5):1330-1336. doi: 10.1378/chest.12-0528
  46. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Feb 5;73(4):457-476. doi: 10.1016/j.jacc.2018.10.075
  47. Wollein U, Schech B, Hardt J, Schramek N. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman. J Pharm Biomed Anal. 2016 Feb 20;120:100-5. doi: 10.1016/j.jpba.2015.12.006
  48. Nauwelaerts N, Ceulemans M, Deferm N, et al. Case Report: Bosentan and Sildenafil Exposure in Human Milk - A Contribution From the ConcePTION Project. Front Pharmacol. 2022 Jun 15;13:881084. doi: 10.3389/fphar.2022.881084
  49. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda, MD: National Institute of Child Health and Human Development; 2006-2023. Sildenafil; 2022 Jul 18 [cited 2023 Dec 29]. Available at: https://pubmed.ncbi.nlm.nih.gov/29999677
  50. Nauwelaerts N, Ceulemans M, Deferm N, et al. Case Report: Bosentan and Sildenafil Exposure in Human Milk - A Contribution From the ConcePTION Project. Front Pharmacol. 2022 Jun 15;13:881084. doi: 10.3389/fphar.2022.881084
  51. Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. Eisenmenger’s syndrome in a 27 week pregnancy--management with bosentan and sildenafil. Ir Med J. 2005 Mar;98(3):87-8. PMID: 15869069
DOI: https://doi.org/10.14797/mdcvj.1308 | Journal eISSN: 1947-6108
Language: English
Page range: 70 - 80
Submitted on: Nov 15, 2023
Accepted on: Dec 20, 2023
Published on: Mar 14, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2024 Eunwoo Park, Zeenat Safdar, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.